Last checked at 
LONDON (Alliance News) - AstraZeneca PLC on Tuesday said trial results of Calquence showed significant increase in time patients lived without progression of chronic lymphocytic leukaemia disease.
Shares in the pharmaceutical company were up 1.4% at 5,823.00 pence each in morning trade.
AstraZeneca said positive results from the Phase III ASCEND trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Calquence monotherapy compared to a combination regimen of rituximab plus physician's choice of idelalisib or bendamustine.
Importantly, the safety and tolerability of Calquence was consistent with the known profile.
"Calquence is the first BTK inhibitor to show benefit in a Phase III trial as a monotherapy compared to current standard-of-care combinations used in relapsed or refractory chronic lymphocytic leukaemia. We look forward to presenting detailed results at a forthcoming medical meeting," said Astra's Oncology Research & Development Vice President Jose Baselga said.
Calquence is currently approved for the treatment of adults with relapsed or refractory mantle cell lymphoma in the US, Brazil, the UAE, and Qatar, and is being developed for the treatment of chronic lymphocytic leukaemia and other blood cancers.
